Pfizer, Cytoo to develop DMD muscle-on-a-plate platform

Pfizer Inc. (NYSE:PFE) partnered with Cytoo S.A. (Grenoble, France) to modify Cytoo’s MyoScreen platform in order to use it as a target discovery platform for Duchenne muscular dystrophy (DMD). The platform is a muscle-on-a-plate derived from patients’ primary cells which mimics the morphology, contractile and metabolic functions of human muscle in vivo.

Pfizer will have an option to acquire a license to the modified platform. Financial terms were not disclosed...